UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)

TG THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, \$0.001 Par Value

(Title of Class of Securities)

88322Q108

(CUSIP Number)

December 31, 2015

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)
 ⊠ Rule 13d-1(c)
 □ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 88322Q108

	NAME OF REPORTING PERSON .R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)								
	Bridger Management, LLC								
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o (b) x								
3	SEC USE ONLY								
4	CITIZENSHIP OR PLACE OF ORGANIZATION								
	Delaware								
NUMBER OF SHARES		5	SOLE VOTING POWER						
BENEFICIALLY OWNED BY		6	SHARED VOTING POWER 3,430,367 ⁽¹⁾						
RI	EACH REPORTING		SOLE DISPOSITIVE POWER						
PERSON WITH		8	SHARED DISPOSITIVE POWER 3,430,367 ⁽¹⁾						
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON								
	3,430,367 ⁽¹⁾								
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 0								
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)								
	6.5%(2)								
12	TYPE OF REPORTING PERSON*								
	IA								

(1) Represents the Reporting Person's beneficial ownership as of February 16, 2016. The Reporting Person's beneficial ownership as of December 31, 2015 was 3,068,315.

(2) Represents the percentage as of February 16, 2016. As of December 31, 2015, such percentage was 5.8%. Such percentages are based on 52,519,686 shares of common stock outstanding as of November 6, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015.

SCHEDULE 13G

CUSIP No. 88322Q108

	1 NAME OF REPORTING PERSON									
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)									
	Roberto Mignone									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o									
			(b) x							
3	SEC USE ONLY									
4	CITIZENSHIP OR PLACE OF ORGANIZATION									
-										
	United States									
NU	UMBER OF	5	SOLE VOTING POWER							
	SHARES	5								
			0							
	NEFICIALLY	6	SHARED VOTING POWER							
0	WNED BY	_	3,430,367(1)							
	EACH		SOLE DISPOSITIVE POWER							
RI	REPORTING									
			0							
-	PERSON		SHARED DISPOSITIVE POWER							
	WITH		2,420,267(1)							
	ACCDECATE A	MOUN	3,430,367 ⁽¹⁾ NT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
9	AGGREGALE A	MOUN	NI BENEFICIALLI OWNED BI EACH REPORTING PERSON							
	3,430,367(1)									
10										
10										
11	PERCENT OF C		REDRESENTED BY AMOUNT IN ROW (9)							
11	1 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)									
	6.5%(2)									
12	TYPE OF REPO	PERSON*								
	INI									
	IN									

(1) Represents the Reporting Person's beneficial ownership as of February 16, 2016. The Reporting Person's beneficial ownership as of December 31, 2015 was 3,068,315.

(2) Represents the percentage as of February 16, 2016. As of December 31, 2015, such percentage was 5.8%. Such percentages are based on 52,519,686 shares of common stock outstanding as of November 6, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015.

Item 1(b).

3 Columbus Circle, 15th Floor, New York, New York 10019

Item 2(a, b, c).

Name of Issuer: TG Therapeutics, Inc.

Address of Issuer's Principal Executive Offices:

Name of Persons Filing, Address of Principal Business Office, Citizenship:

Bridger Management, LLC, a Delaware limited liability company, 90 Park Avenue – 40th Floor, New York, NY 10016

Mr. Roberto Mignone ("Mr. Mignone"), 90 Park Avenue – 40th Floor, New York, NY 10016. Mr. Mignone is a United States citizen.

Item 2(d).	Title of Class of Securities: Common Stock, \$0.001 Par Value (the "Common Stock")
Item 2(e).	CUSIP Number: 88322Q108
Item 3.	Not Applicable.
Item 4.	Ownership.
	Information with respect to the Reporting Persons' ownership of the Common Stock as of February 16, 2016 and December 31, 2015, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.
	Swiftcurrent Offshore

Master Ltd., Swiftcurrent Partners L.P. and Bridger Healthcare, Ltd. are the owners of record of the Common Stock reported herein. Bridger Management LLC is the investment adviser to Swiftcurrent Offshore Master Ltd., Swiftcurrent Partners L.P. and Bridger Healthcare, Ltd. Mr. Mignone is the manager of Bridger Management, LLC. Each of Bridger Management LLC and Mr. Mignone may be deemed to share beneficial ownership of the Common Stock reported herein.

Ownership of Five Percent or less of a Class:

Ownership of More than Five Percent on Behalf of Another Person.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding

Item 5.

Not Applicable

Item 6.

See Item 4.

Item 7.

Company or Control Person.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Not Applicable.

Item 10.

Certification.

Notice of Dissolution of Group.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

[Signature Page Follows:]

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATED: February 16, 2016

BRIDGER MANAGEMENT, LLC

By: <u>/s/ Roberto Mignone</u> Roberto Mignone, Manager

/s/ Roberto Mignone

Roberto Mignone, Individually

Exhibit I: Joint Filing Statement Pursuant to Rule 13d-1(k)

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: February 16, 2016

BRIDGER MANAGEMENT, LLC

By: /s/ Roberto Mignone Roberto Mignone, Manager

/s/ Roberto Mignone

Roberto Mignone, Individually